Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Diagnosis of active tuberculosis (TB) is the first step to determine the next treatment management of patient care. The success of the treatment will not be achieved without the determined accurate diagnosis rapidly. The definitive diagnosis of tuberculosis includes the presence of Mycobacterium tuberculosis through smear staining or histopathological examination or culture method or molecular methods, however some of the methods have limitations for TB diagnosis, especially on extrapulmonary tuberculosis (EPTB). In EPTB, culture method is time consuming till 6-8 weeks, where as it requires a rapid diagnosis, while tissue biopsy to obtain histopathological images is an invasive procedure. Likewise, the constrains on determining diagnosis of pulmonary TB (PTB) especially child TB and EPTB. In certain condition, the detected ADA level exceeds the detection limit as well as in TB disease with an active process. To study the meaning detection of Serum Adenosis Deaminase in serum of patients as an indicator in diagnosing of active disease process in Pulmonary and Extra Pulmonary Tuberculosis. This study was an observational study with a cross sectional study method, carried out in 8 months, by taking serum of blood samples from patients diagnosed with PTB and EPTB. The sample examination, then measuring the ADA serum levels using the ELISA method in Dr Ramelan Hospital Surabaya Indonesia, and cofirmed MTBC in blood samples using standard PCR of gyrB gene region in the Tuberculosis Laboratory, Tropical Disease Institute, Airlangga University, Surabaya, Indonesia. In totally 176 serum samples form PTB and EPTB patients, at January 2020 until December 2020, there were no significant results between serum Adenosine Deaminase (ADA) levels in diagnosing Pulmonary Tuberculosis and Extra Pulmonary Tuberculosis at Dr. Ramelan Hospital Surabaya. So, in this study, ADA serum levels could have the potential role in the diagnosis of pulmonary tuberculosis and EPTB, otherwise this study revealed that ADA serum activity is not a useful test for differentiating tuberculosis from other respiratory diseases, and could be an additional test especially for disease active progressive or recovery.
Diagnosis of active tuberculosis (TB) is the first step to determine the next treatment management of patient care. The success of the treatment will not be achieved without the determined accurate diagnosis rapidly. The definitive diagnosis of tuberculosis includes the presence of Mycobacterium tuberculosis through smear staining or histopathological examination or culture method or molecular methods, however some of the methods have limitations for TB diagnosis, especially on extrapulmonary tuberculosis (EPTB). In EPTB, culture method is time consuming till 6-8 weeks, where as it requires a rapid diagnosis, while tissue biopsy to obtain histopathological images is an invasive procedure. Likewise, the constrains on determining diagnosis of pulmonary TB (PTB) especially child TB and EPTB. In certain condition, the detected ADA level exceeds the detection limit as well as in TB disease with an active process. To study the meaning detection of Serum Adenosis Deaminase in serum of patients as an indicator in diagnosing of active disease process in Pulmonary and Extra Pulmonary Tuberculosis. This study was an observational study with a cross sectional study method, carried out in 8 months, by taking serum of blood samples from patients diagnosed with PTB and EPTB. The sample examination, then measuring the ADA serum levels using the ELISA method in Dr Ramelan Hospital Surabaya Indonesia, and cofirmed MTBC in blood samples using standard PCR of gyrB gene region in the Tuberculosis Laboratory, Tropical Disease Institute, Airlangga University, Surabaya, Indonesia. In totally 176 serum samples form PTB and EPTB patients, at January 2020 until December 2020, there were no significant results between serum Adenosine Deaminase (ADA) levels in diagnosing Pulmonary Tuberculosis and Extra Pulmonary Tuberculosis at Dr. Ramelan Hospital Surabaya. So, in this study, ADA serum levels could have the potential role in the diagnosis of pulmonary tuberculosis and EPTB, otherwise this study revealed that ADA serum activity is not a useful test for differentiating tuberculosis from other respiratory diseases, and could be an additional test especially for disease active progressive or recovery.
India, with increased burden of tuberculosis (TB) cases, mandates the search for alternative antimycobacterial drugs. Medicinal plants have the potential to act against the mycobacterium with less or no side effects like hepatotoxicity caused by the most anti-TB drugs. This study is aimed to investigate the antimycobacterial activity of various extracts of whole plant, Aristolochia bracteolata against Mycobacterium tuberculosis H37Rv and hepatoprotective activity against anti-TB drug induced hepatotoxicity in HepG2 cell line. Microplate Alamar Blue Assay (MABA) is used to determine the Minimum Inhibitory Concentration (MIC) of samples for antimycobacterial activity and 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) assay to determine the effect of extract and standard, silymarin on isoniazid (INH) induced toxicity in HepG2 cells, based on the cell viability. The whole plant was extracted using petroleum ether, ethyl acetate and ethanol based on the polarity of solvents in the Soxhlet extractor successively and their yield value is determined. Phytochemical screening revealed the presence of constituents like alkaloids, terpenoids, flavonoids, phenols, tannins, saponin, steroids, carbohydrates and proteins. The results of MIC on Mycobacterium showed that the petroleum ether extract possess good antimycobacterial activity at 25µg/ml. It also showed good hepatoprotective activity against INH induced toxicity on increasing concentrations. So, the plant has the potential to act as adjunct to TB chemotherapy.
Tuberculosis or TB caused by the micro-organism Mycobacterium tuberculosis is a highly contagious and the second most fatal disease after AIDS. It is estimated that it will soon surpass the deaths caused by HIV.BCG is the only vaccine available to prevent TB, however it is not effective in case of adult pulmonary TB which is actually the most common type of TB. The currently used treatment regimen in most developing countries is a single tablet with fixed dose combination of four drugs- Isoniazid (INH), Rifampicin, Ethambutol and Pyrazinamide which are 1st line anti-tubercular drugs. This combination reduces the risk of development of multi-drug resistant (MDR) Mycobacterium. But this drug combination is known to have various severe side-effects, which if not taken into consideration might lead to fatal reactions. MDR-TB treatment involves the use of 2nd line drugs which are less potent and more toxic compared to 1st line drugs. Increasing number of MDR strains of mycobacterium and failure of these conventional regimens to treat them is a huge challenge. Also, these side-effects associated with anti-TB drugs are a major reason for patient non-compliance and non-adherence to the treatment. Treatment discontinuation leads to increased risk of mortality and morbidity due to TB. Thus, it is very important to develop new therapeutic approaches towards the treatment of this disease which provide a better cure without relapse, lesser side-effects and prevents formation of drug resistant strains. The article reviews the various side-effects associated with the Anti-Tubercular drugs that are currently used and discusses certain newer, nanoparticle-basedapproaches to overcome the shortcomings of the current conventional therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.